Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Glioblastoma × amivantamab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 3 Solid Tumors 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Head and Neck Neoplasms 1 Glioblastoma 1 Colorectal Neoplasms 1 Breast Neoplasms 1

Interventions

Temozolomide 99 Radiotherapy 56 Radiation 26 Bevacizumab 17 Magnetic Resonance Spectroscopy 13 Nivolumab 11 Irinotecan 10 Cyclophosphamide 9 Surgical Procedures, Operative 8 Specimen Handling 8 pembrolizumab 7 motexafin gadolinium 7 Radiotherapy, Intensity-Modulated 7 Radiosurgery 7 O(6)-benzylguanine 7 Flucytosine 7 Chemotherapy, Adjuvant 7 sargramostim 6 poly ICLC 6 Leukapheresis 6 Erlotinib Hydrochloride 6 Carmustine 6 fludarabine 5 Radiotherapy, Conformal 5 Lomustine 5 Imiquimod 5 Imatinib Mesylate 5 Hydroxyurea 5 Drug Therapy 5 vocimagene amiretrorepvec 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06632236 2025-04-25

5G-EMERALD

Institute of Cancer Research, United Kingdom

Phase 1 Recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡